Satyashodhan Patil

Founder

The global landscape for medical devices and drug-device combination products is not just evolving, but shaping the way healthcare is delivered across the world. Starting as specialized innovation in regulated markets, these solutions have become a global movement driven by the rising need for patient-centered solutions.

Convenience, accuracy, safety, and highest level of therapeutic outcomes are the need of the hour. India mirrors this global momentum, with emphasis on accessibility, quality, and affordability becoming paramount.

Yet, the path to innovation is more complex than ever as pharmaceutical science and engineering converge, creating a demand for cross-functional expertise. Simultaneously, stringent regulatory frameworks in the global market add layers of regulatory complexity and risk.

Possessing expertise at this intersection is Solapur’s INNDEVICE Research, a specialized partner that bridges the gap between pharmaceutical and medical device industries. Built on the belief that healthcare innovation demands unmatched cross-function expertise, the company, founded by industry veteran Satyashodhan Patil, represents a new generation of solutions providers.

Offering end-to-end capabilities while reinventing how innovation is conceptualized, developed, and delivered, the company enables organizations to create high-value patient-oriented solutions aligning with global standards.

Unifying A Fragmented Segment

INNDEVICE’s foundation was inspired by the clear recognition of a systemic gap within the sector. Rather than the usual service provider in a pool of thousands, INNDEVICE distinguished itself through first-hand experience within the global pharmaceutical environments.

In a sector where pharmaceutical expertise remains disconnected with device engineering experience, thereby compromising on innovation in drug-device combination products, INNDEVICE developed a platform that serves multiple organizations across these segments.

“I established this company to support and guide medical device, pharma and life sciences companies for effective col­laboration and successful new medical device development to provide healthcare solutions.

With in-depth knowledge, exten­sive experience and a successful track record in innovation, research and development of medial devices, pharmaceutical and life sciences products, we create a meaningful impact to redefine healthcare”, shares Satyashodhan Patil, Founder, IN­NDEVICE Research.

With extensive experience leading device development for global markets and working across organizations such as Sun Pharma, Johnson & Johnson, and GE Healthcare, Satyashodhan’s exposure enables the company to understand the practical realities of navigating product development, approvals, compliance, and commercialization.

At the same time, the company cemented its position as a knowledge integrator, bringing together engineering best practices from across industries and applying them to pharmaceutical-device innovation.

Comprehensive Capabilities That Stand Out

INNDEVICE's core strength lies in its ability to deliver com­prehensive, end-to-end solutions across the entire lifecycle of medical device and drug-device combination product devel­opment. This includes conceptualization, design and develop­ment, manufacturing support, regulatory compliance, quality systems, technical consulting, and training. What differentiates the company is not just the breadth of services, but the depth of integration across them.

Unlike fragmented service models, where different aspects of development are handled by separate vendors; INNDEVICE offers a unified approach that ensures continuity, consistency, and quality across every stage. This significantly reduces inefficiencies, misalignment, and delays that are common in complex product development cycles.

It has been experienced that pharma companies needs engineering expertise required at every stage of drug-device combination product (DDCP) development right from conceptualization, device development, meeting regulatory and quality compliance to approvals and product life cycle management (PLM).

Lack of engineering expertise results into either application refusal to review or with several queries or information requests from regulatory agencies consequently ends with either delay in product approval or withdrawal of application.

"INNDEVICE Research is India’s first start-up which offers end-to-end services to both pharma and device industry from front-end innovation, conceptualization, new product development to technical support for commercialization, connecting both together with the highest level of quality and affordable services for drug-device combination product development”, adds Satyashodhan.

The company’s capabilities span conceptualization and product design, engineering development and manufacturing support, regulatory strategy and compliance, quality systems and documentation, and training and capability development for client teams. Its comprehensive scope allows clients to move seamlessly from concept to commercialization without the inefficiencies that come with fragmented execution. At the same time, INNDEVICE maintains a strong focus on cost effi­ciency.

By optimising development processes and reducing in­efficiencies, the company ensures that high-quality innovation does not come at prohibitive costs, making advanced health­care solutions and self-administration drug-device combina­tion products more accessible and affordable across markets. With these kinds of services for pharma and medical device industries, INNDEVICE expects a revolution in affordability and availability of complex high value drug-device combina­tion products in coming few years.

The self-administration patient-centric drug delivery devices such as pen injectors au­to-injectors, PFSs, inhalers, infusion pumps, eye droppers, nasal sprays, applicators and implantable devices will be available, accessible and affordable across the geographies benefitting to the patients.

These devices with drug integration are being used to treat several illnesses ranging from diabetes, obesity, migraine, osteoporosis, rheumatoid arthritis to multiple sclero­sis, asthma, COPD, psoriasis, dry eye disease, hormonal changes and many more.

Regulatory, Quality, and Development Focus

The medical device and drug-device combination space is inherently complex, with multiple layers of regulatory, technical, and operational challenges. For pharmaceutical companies, one of the most significant hurdles is adapting to device-specific requirements; particularly in areas such as engineering verification and validation, human factors, and design controls, which are often outside traditional pharma expertise.

Furthermore, the company supports clients in navigating global regulatory landscapes, including US FDA requirements, European Medical Device Regulations (EU MDR), and ISO standards, going beyond compliance to include interpretation and implementation aligned with product design and development.

Through structured processes, standard operating procedures, and robust documentation frameworks, INNDEVICE ensures that products meet regulatory expectations from the outset while maintaining consistency and quality across development stages.

In addition, the company addresses operational inefficiencies, such as delays, lack of approvals, and poor documentation practices, by implementing structured systems that ensure consistency, quality, and speed across projects. This ability to transform fragmented challenges into system-driven solutions positions Inn Device as a critical problem-solver in the industry.

Tech-Focused Future Innovations

Innovation at INNDEVICE extends beyond product development into the systems, tools, and methodologies that support it. The company actively integrates emerging technologies such as artificial intelligence, automation, and digital platforms to enhance efficiency and decision-making across development processes.

AI, in particular, plays a critical role in early-stage development, supporting design inputs, regulatory research, and patent analysis. This allows for faster, more informed decision-making while reducing the risk of design conflicts or regulatory misalignment.

Beyond AI, the company is advancing digitisation and automation across its operations, implementing paperless documentation systems, digital approvals, and automated testing processes for drug delivery devices. These enhancements not only improve efficiency but also ensure consistency and traceability in highly regulated environments.

“At INNDEVICE, our purpose is to research & revolutionize best in-class patient-centric medical devices. Our vision is to redefine healthcare and identify ourselves as a pioneer in creating best solutions for medical challenges.

Our mission is to innovate or guide or collaborate with medical technology and pharmaceutical industries to empathetically develop unique, next generation, patient-centric medical devices. These key pillars have shaped our direction, and continue guiding where we go in the future”, concludes Satyashodhan.

Looking ahead, INNDEVICE’s growth strategy is centred on expansion and collaboration. By building partnerships with testing laboratories, manufacturing organisations, and industry stakeholders, the company aims to create a more integrated and efficient development ecosystem.

At the same time, it continues to invest in innovation, particularly in user-friendly drug delivery systems that can improve patient experience and outcomes. This includes the development of new concepts and technologies that have the potential to shape future therapies.

The broader industry trajectory reinforces this direction. Growth is being driven by multiple interconnected factors, including patent dynamics, infrastructure development, regulatory evolution, cost pressures, and the need for cross-disciplinary collaboration.

By aligning itself with these drivers, INNDEVICE is not only responding to industry needs but actively contributing to a more integrated, accessible, and innovation-led future for medical device and drug-device combination development.

A Force To Reckon

- Behind this pioneering organization is a founder who brings extensive knowledge and expertise garnered over years.

- Satyashodhan Patil has worked in the R&D departments of giants like Sun Pharmaceutical Industries Ltd., Johnson and Johnson Medical, and GE Healthcare gaining first-hand knowledge of global regulatory standards in medical device development.

- In a remarkable career spanning 23+ years, he has authored numerous researches, pioneered the implementation of Design History File (DHF) system in Indian pharma industry, developed patient-centric devices, and registered several patents.